Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial

This publication has 23 references indexed in Scilit:

• Randomized, Placebo‐Controlled Trial of HA‐1A, a Human Monoclonal Antibody to Endotoxin, in Children with Meningococcal Septic Shock
  Clinical Infectious Diseases, 1999
• Pathophysiology of meningococcal sepsis in children
  European Journal of Pediatrics, 1998
• Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis
  The Lancet, 1997
• An N-terminal fragment of bactericidal/permeability-increasing protein protects against hemodynamic and metabolic derangements in rat Gram-negative sepsis
  Innate Immunity, 1996
• Inhibition of Endotoxin-Induced Cytokine Release and Neutrophil Activation in Humans by Use of Recombinant Bactericidal/Permeability-Increasing Protein
  The Journal of Infectious Diseases, 1995
• Pathogenesis of Hemorrhage-Induced Bacteria/Endotoxin Translocation in Rats Effects of Recombinant Bactericidal/Permeability-Increasing Protein
  Annals of Surgery, 1995
• Coagulopathy as a predictor of outcome in meningococcal sepsis and the systemic inflammatory response syndrome with purpura
  Critical Care Medicine, 1993
• Assessing the outcome of pediatric intensive care
  The Journal of Pediatrics, 1992
• Validation of the Glasgow Meningococcal Septicemia Prognostic Score
  Critical Care Medicine, 1991
• Factors for Poor Prognosis in Fulminating Meningococcemia
  Clinical Pediatrics, 1978